ABSTRACT
BACKGROUND:
Preclinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In this study, we evaluated whether imaging with sst antagonists was feasible in patients.
METHODS:
Biodistribution and tumor uptake of the sst antagonist (111)In-DOTA-pNO(2)-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)DTyrNH(2) ((111)In-DOTA-BASS) were studied in 5 patients with metastatic thyroid carcinoma or neuroendocrine tumors. Findings were compared with (111)In-pentetreotid ((111)In-DTPA-octreotide) scan.
RESULTS:
No adverse effects of (111)In-DOTA-BASS (20 μg) were observed. (111)In-DOTA-BASS detected 25 of 28 lesions, whereas (111)In-DTPA-octreotide detected only 17 of 28 lesions. In the same patient, (111)In-DOTA-BASS showed higher tumor and lower renal uptake than (111)In-DTPA-octreotide (3.5 ± 2.8 percentage injected activity [%IA] vs. 1.0 ± 0.99%IA and 1.5 ± 0.3 %IA vs. 2.3 ± 0.7 %IA) at 4 h after injection.
CONCLUSION:
Imaging of neuroendocrine tumors with sst antagonists is clinically feasible. The favorable human biodistribution data suggest that sst antagonists could significantly affect peptide receptor-mediated imaging and therapy.
Free full text
First clinical evidence that imaging with somatostatin receptor antagonists is feasible
Riferimento:
J Nucl Med. 2011 Sep;52(9):1412-7.
Autori:
Wild D1, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, Maecke HR, Weber WA.
Fonte:
J Nucl Med. 2011 Sep;52(9):1412-7.
Anno:
2011
Azione:
I recettori della somatostatina (SST) potrebbero influenzare in modo significativo l'imaging e la terapia nel carcinoma della tiroide metastatico e nei tumori neuroendocrini.
Target:
Recettori della somatostatina/carcinoma della tiroide metastatico - tumori neuroendocrini.
Sostanze: